GLAXOSMITHKLINE PHARMA A/S: Financial statements 2013
CVR: 27394019
Source: annual report 2013, Danish Business Authority
01/01/2013 – 31/12/2013
GLAXOSMITHKLINE PHARMA A/S (CVR 27394019) has filed annual accounts for 2013. In 2013, the company reported revenue of DKK 364,257,000 and a net result of DKK 14,472,000. The profit margin was 4%. Equity in the 2013 report amounted to DKK 146,906,000. The solvency ratio was 55%. The company had 109 employees in the financial year.
- Revenue
- DKK 364,257,000
- Gross Profit
- DKK 126,968,000
- Profit/Loss
- DKK 14,472,000
- Equity
- DKK 146,906,000
- Total Assets
- DKK 266,969,000
- Employees
- 109
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2013
As of October 11, 2013, Judith Lynne Stewart has joined the board of directors of GLAXOSMITHKLINE PHARMA A/S.
As of October 11, 2013, Birgit Yvonne Reimann has joined the board of directors of GLAXOSMITHKLINE PHARMA A/S.
As of October 11, 2013, Georgios Katzourakis has left the board of directors of GLAXOSMITHKLINE PHARMA A/S.
As of October 11, 2013, Judith Lynne Stewart is registered as adm. dir. of GLAXOSMITHKLINE PHARMA A/S.
As of October 11, 2013, Birgit Yvonne Reimann has stepped down as adm. dir. of GLAXOSMITHKLINE PHARMA A/S.
GLAXOSMITHKLINE PHARMA A/S has published its annual report for 2012.
About GLAXOSMITHKLINE PHARMA A/S
GLAXOSMITHKLINE PHARMA A/S is a Danish company of the type Aktieselskab based in Vallensbæk Strand, founded in 1968. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named GLAXO DANMARK A/S and GLAXO WELLCOME A/S. The management consists of Diederik Maarten Eijsvogel. The board consists of Luciano Alves de Andrade (chair), Alastair William Jones, Diederik Maarten Eijsvogel and Helle Ann Hellberg. The company is owned by Setfirst Limited. The company has 83 employees (2026). In 2025, the company reported revenue of DKK 580,769,000 and a net result of DKK 13,123,000 compared with DKK 12,240,000 the year before. Equity in the 2025 report amounted to DKK 39,017,000.